Hansa Biopharma AB, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on the stock and has a SEK143.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Hansa Biopharma AB’s potential for growth and innovation in the gene therapy space. The company’s imlifidase product has shown promising results in reducing pre-existing anti-AAV antibodies by 95% in patients with Duchenne muscular dystrophy (DMD), enabling them to receive gene therapy treatments like Elevidys. This breakthrough could significantly expand the pool of eligible patients for AAV-based gene therapies, addressing a major barrier in the field and potentially increasing revenue opportunities.
Furthermore, Hansa Biopharma’s valuation is supported by a risk-adjusted revenue estimate, with a price target of SEK143 based on a 5.8x multiple of the projected 2035 revenue. The company’s pipeline includes several promising assets, such as highly sensitized kidney transplants and Goodpasture syndrome, which have shown positive progress in clinical trials. However, there are risks associated with financial needs, regulatory approvals, and partnerships, particularly with Sarepta, which could impact future outcomes. Despite these challenges, the potential efficacy of imlifidase and the strategic collaborations position Hansa Biopharma well for future success.